Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ekso Bionics Holdings (EKSO) Other Non-Current Assets (2016 - 2025)

Ekso Bionics Holdings (EKSO) has disclosed Other Non-Current Assets for 13 consecutive years, with $311000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Other Non-Current Assets fell 28.18% to $311000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $311000.0, a 28.18% decrease, with the full-year FY2025 number at $311000.0, down 28.18% from a year prior.
  • Other Non-Current Assets was $311000.0 for Q4 2025 at Ekso Bionics Holdings, down from $413000.0 in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $531000.0 in Q3 2024 to a low of $125000.0 in Q3 2021.
  • A 5-year average of $297700.0 and a median of $295000.0 in 2023 define the central range for Other Non-Current Assets.
  • Peak YoY movement for Other Non-Current Assets: crashed 48.75% in 2021, then surged 159.38% in 2023.
  • Ekso Bionics Holdings' Other Non-Current Assets stood at $164000.0 in 2021, then surged by 40.85% to $231000.0 in 2022, then skyrocketed by 69.7% to $392000.0 in 2023, then rose by 10.46% to $433000.0 in 2024, then dropped by 28.18% to $311000.0 in 2025.
  • Per Business Quant, the three most recent readings for EKSO's Other Non-Current Assets are $311000.0 (Q4 2025), $413000.0 (Q3 2025), and $362000.0 (Q2 2025).